TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 5317541
Drug: Metaproterenol oral
Normalized name: metaproterenol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol oral tablets (20 to 80 mg daily for an average of about three weeks)
Study: 26152418
Drug: Emodepside/Praziquantel solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emodepside/Praziquantel solution (3 mg/kg emodepside and 12 mg/kg praziquantel)
Study: 3485398
Drug: Intranasal nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal nifedipine
Study: 30412065
Drug: On-demand therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand therapy with esomeprazole 40 mg
Study: 30412065
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy with esomeprazole 20 mg
Study: 19919569
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg/day combined with peginterferon (Peg‐IFN)‐alpha‐2b/ribavirin (RBV) for 48 weeks
Study: 18990058
Drug: Adenovirus type
Normalized name: Adenovirus types 4 and 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenovirus type 5 (Ad5)‐vectored clade B HIV‐1 monovalent gag and trivalent gag/pol/nef vaccines
Study: 18990058
Drug: Adenovirus type
Normalized name: Adenovirus types 4 and 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenovirus type 5 (Ad5)‐vectored clade B HIV‐1 vaccines with >or=1 x 10(10) gag‐containing Ad5 particles per dose
Study: 18990058
Drug: Adenovirus type
Normalized name: Adenovirus types 4 and 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenovirus type 5 (Ad5)‐vectored clade B HIV‐1 vaccines
Study: 19675365
Drug: Moderate alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate alcohol dose
Study: 11051345
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg b.i.d.) for 2 weeks followed by clarithromycin (250 mg b.i.d.) and metronidazole (500 mg b.i.d.) for 1 week
Study: 11051345
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg b.i.d.) for 2 weeks followed by clarithromycin (250 mg b.i.d.) and metronidazole (500 mg b.i.d.) for 1 week
Study: 11051345
Drug: Pantoprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (40 mg b.i.d.) for 2 weeks followed by clarithromycin (250 mg b.i.d.) and metronidazole (500 mg b.i.d.) for 1 week
Study: 3979000
Drug: Dazoxiben (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dazoxiben (100 mg, intravenously every 4 hours for a maximum of 72 hours)
Study: 24720918
Drug: Sitaxsentan 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxsentan 100 mg/day
Study: 22578518
Drug: Anthracycline chemotherapy
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracycline chemotherapy (mean dose, 296 ± 103 mg/m²)
Study: 20880151
Drug: Propofol loading
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol loading dose administered over 3.0 min (4 mg·kg(‐1))
Study: 20880151
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 200 mcg·kg(‐1)·min(‐1) for 5 min or until respiratory insufficiency observed
Study: 11322207
Drug: 5 MU
Normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 MU of interferon (IFN) tiw plus ribavirin (1000‐1200 mg/daily) for 12 months
Study: 11322207
Drug: 5 MU
Normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 MU of interferon (IFN) tiw monotherapy
Study: 9130939
Drug: Hib polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib polysaccharide tetanus protein (PRP-T) mixed with diphtheria-tetanus-pertussis vaccine (DTP)
Study: 8433727
Drug: Thrombolytic agent
Normalized name: Thrombolytic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic agent (tissue plasminogen activator)
Study: 8433727
Drug: Immediate angioplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate angioplasty and thrombolytic agent
Study: 3314973
Drug: Acyclovir 400
Normalized name: acyclovir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 400 mg, 5 times a day for 5 days
Study: 3314973
Drug: Acyclovir 400
Normalized name: acyclovir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 400 mg and Placebo
Study: 23937975
Drug: Stepped-care programme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped-care programme (watchful waiting, guided self-help, problem solving treatment, referral to general practitioner)
Study: 20562124
Drug: Azithromycin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (n = 40), administered three times a week for 2 years
Study: 16507189
Drug: Inhalation induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation induction with sevoflurane followed by subhypnotic dose of propofol (1 mg kg‐1)
Study: 16507189
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol induction
Study: 11055098
Drug: Zinc nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc nasal gel (Zicam)
Study: 8927940
Drug: Modified-release amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release amoxicillin tablet
Study: 28931127
Drug: 1 standard
Normalized name: Kroger Universal 1 Standard Lancet 21G
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 standard dose IM dose of PVRV
Study: 28931127
Drug: 1/5th‐fractional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/5th‐fractional dose ID of PVRV
Study: 28931127
Drug: 2/5th‐fractional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2/5th‐fractional dose ID of PVRV
Study: 28931127
Drug: 3/5th‐fractional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3/5th‐fractional dose ID of PVRV
Study: 25055554
Drug: Intravenous ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ozone therapy and small doses of direct current (20-25mkA)
Study: 16186468
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with aspirin alone
Study: 16186468
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus colchicine (1.0-2.0 mg the first day and then 0.5-1.0 mg/d for 6 months)
Study: 1906935
Drug: Gold sodium
Normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold sodium thiomalate (GSTM) 50 mg intramuscularly for 6 months
Study: 1906935
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg intramuscularly for 6 months
Study: 6600579
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate (40 mg/kg/day every six hours for seven days)
Study: 30165750
Drug: Clemastine 2
Normalized name: clemastine 2 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine 2 mg (1 mg/ml)
Study: 30165750
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline 2 ml)
Study: 28296735
Drug: Remifentanil (infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (infused at 0.1 μg/kg/min with demand boluses of 0.1 μg/kg)
Study: 27012255
Drug: In-home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-home treatment (preferred modality in choice condition)
Study: 24525810
Drug: Reboxetine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (4 mg twice daily)
Study: 15365306
Drug: Injectable naltrexone
Normalized name: naltrexone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable naltrexone (400 mg, administered intramuscularly once every 28 days for 4 months)
Study: 15365306
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (matching to naltrexone, administered once every 28 days for 4 months)
Study: 11226444
Drug: Constant 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant 17beta‐estradiol (E2), 1 mg, plus intermittent norgestimate (NGM) 90 microg (3 days off, 3 days on)
Study: 11226444
Drug: E2 2
Normalized name: PGE2 20 MG Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 2 mg/norethisterone acetate (NETA) 1 mg
Study: 7986315
Drug: Fluvastatin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 2.5 mg q.p.m.
Study: 7986315
Drug: Fluvastatin 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 5 mg q.p.m.
Study: 7986315
Drug: Fluvastatin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 10 mg q.p.m.
Study: 7986315
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg q.p.m.
Study: 30982442
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose astaxanthin (≥20 mg/day)
Study: 30982442
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose astaxanthin (<20 mg/day)
Study: 26003264
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (including dietary advice)
Study: 23305646
Drug: GcgR agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GcgR agonist
Study: 23305646
Drug: Natural glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Natural glucagon injection
Study: 10390394
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP), 1,000 micrograms twice a day
Study: 10390394
Drug: Budesonide (BUD),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (BUD), 800 micrograms twice a day
Study: 10390394
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP), 200 micrograms twice a day
Study: 10390394
Drug: Budesonide (BUD),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (BUD), 200 micrograms twice a day
Study: 2067759
Drug: Magnesium pyrrolidone
Normalized name: Pyrrolidone
DrugBank: Pyrrolidone (DB19152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium pyrrolidone carboxylic acid (360 mg Mg) administered three times a day from the 15th day of the menstrual cycle to the onset of menstrual flow
Study: 2067759
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered three times a day from the 15th day of the menstrual cycle to the onset of menstrual flow
Study: 6336937
Drug: Intramuscular cephaloridine
Normalized name: cephaloridine
DrugBank: Cefaloridine (DB09008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular cephaloridine (three 1-g perioperative doses)
Study: 6336937
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin base and neomycin sulfate (three 1-g preoperative doses)
Study: 28051337
Drug: Trauma-Focused Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT) for 12 sessions (n=40)
Study: 26695667
Drug: PCT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT group (antibiotic therapy guided by serum procalcitonin)
Study: 26695667
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard therapy according to clinical guidance)
Study: 12671541
Drug: Isoflavone supplement
Normalized name: Soyrel Soy Isoflavone Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplement (100 mg daily)
Study: 11269917
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (2.5% lidocaine and 2.5% prilocaine in oil emulsion) applied 2 hours prior to microneurography
Study: 11269917
Drug: Aqueous placebo
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous placebo cream applied 2 hours prior to microneurography
Study: 8147088
Drug: Complex physical
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex physical therapy (CPT) including special lymphatic massage after surgical reconstruction
Study: 8147088
Drug: Complex physical
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex physical therapy (CPT)
Study: 3524119
Drug: Desenkephalin-gamma-endorphin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desenkephalin-gamma-endorphin (3 mg)
Study: 23946347
Drug: 3.3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.3 g/d oat β-glucans for 3 weeks
Study: 23946347
Drug: 3.3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.3 g/d oat β-glucans
Study: 10942739
Drug: Lotrafiban 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotrafiban 5 mg
Study: 10942739
Drug: Lotrafiban 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotrafiban 100 mg
Study: 10942739
Drug: Lotrafiban (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotrafiban (all doses)
Study: 8769625
Drug: Pentoxifylline administered
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline administered intravenously 90 min before penicillin injection
Study: 3532771
Drug: Dialysate calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate calcium of 2.5 mEq/L
Study: 3532771
Drug: Dialysate calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate calcium of 3.5 mEq/L
Study: 29749113
Drug: Initial anti-viral
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial anti-viral therapy (valaciclovir 500-1000 mg 1-3 times daily, aciclovir 200-400 mg 1-5 times daily, topical aciclovir 2-5 times daily, topical trifluorothymidine two hourly or as needed)
Study: 29749113
Drug: Evidence-based anti-viral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based anti-viral therapy
Study: 29749113
Drug: Indication and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indication and dose of prescribed anti-virals
Study: 26248652
Drug: Venlafaxine extended
Normalized name: Desvenlafaxine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine extended release (37.5 mg), twice daily, through last dose of oxaliplatin
Study: 21208597
Drug: Zolpidem extended-release
Normalized name: zolpidem Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem extended-release 12.5 mg/night
Study: 21208597
Drug: Zolpidem extended-release/escitalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem extended-release/escitalopram
Study: 12269458
Drug: Toothpaste containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothpaste containing 440 ppmF (Colgate 0‐6 Gel)
Study: 9494149
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 microg four times daily)
Study: 9494149
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole (maintenance therapy)
Study: 9494149
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 microg twice daily, maintenance therapy)
Study: 9494149
Drug: Placebo (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maintenance therapy)
Study: 8033494
Drug: Torsemide 50
Normalized name: torsemide 50 MG in 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torsemide 50 mg
Study: 8033494
Drug: Torsemide 100
Normalized name: torsemide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torsemide 100 mg
Study: 8033494
Drug: Torsemide 200
Normalized name: torsemide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torsemide 200 mg
Study: 12366873
Drug: S-adenosyl-L-methionine (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (SAMe) 800 mg in 250 ml isotonic solution
Study: 12366873
Drug: Placebo 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 250 ml isotonic solution
Study: 29796649
Drug: Two Letters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two Letters + Counseling Call (CC arm)
Study: 29804416
Drug: Mild hypothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hypothermia therapy (maintained at 35±1 ℃ for 5-7 days)
Study: 29804416
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (RT) including bloody cerebrospinal fluid drainage, spasmolysis, 3H treatment, etc.
Study: 24832638
Drug: Paclitaxel drug‐eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel drug‐eluting balloons (pDEB) plus bare metal stent (BMS)
Study: 22396515
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 50 mg/wk + placebo
Study: 22396515
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 125 mg/wk + placebo
Study: 22396515
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 300 mg/wk + placebo
Study: 22396515
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 600 mg/wk + placebo
Study: 22396515
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 50 mg/wk + dutasteride
Study: 22396515
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 125 mg/wk + dutasteride
Study: 22396515
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 300 mg/wk + dutasteride
Study: 22396515
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 600 mg/wk + dutasteride
Study: 16109551
Drug: ACEI (ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI (ramipril starting dose of 2.5 mg/d gradually reaching 5 mg/d)
Study: 16109551
Drug: ARB (irbesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB (irbesartan with gradual increase of doses till reaching maximum daily dose of 150 mg)
Study: 2775616
Drug: Halofantrine 250
Normalized name: halofantrine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine 250 mg fasting
Study: 2775616
Drug: Halofantrine 250
Normalized name: halofantrine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine 250 mg after fatty meal
Study: 2775616
Drug: Halofantrine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine 500 mg
Study: 2775616
Drug: Halofantrine 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine 1000 mg
Study: 2775616
Drug: Halofantrine 250
Normalized name: halofantrine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine 250 mg fasting vs 250 mg after fatty meal
Study: 2775616
Drug: Halofantrine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine 500 mg vs 1000 mg
Study: 29599530
Drug: anti-CD19 CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-CD19 CAR T-cell therapy
Study: 30592549
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin tregopil (IN‐105)
Study: 28415636
Drug: Leflunomide +
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide + low-dose corticosteroid
Study: 28415636
Drug: Full-dose corticosteroid
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose corticosteroid
Study: 25608756
Drug: Prednisone 50
Normalized name: prednisone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 50 mg daily for 7 days
Study: 22696891
Drug: Methylphenidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.3 mg/kg/d + zinc sulfate 10 mg/d (GZN)
Study: 22696891
Drug: Methylphenidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.3 mg/kg/d + placebo (GPL)
Study: 19696423
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg once daily for 10 days)
Study: 19696423
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) (5000 U every 12 hours for 10 days)
Study: 11371662
Drug: Trocade 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trocade 25 mg
Study: 11371662
Drug: Trocade 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trocade 50 mg
Study: 11371662
Drug: Trocade 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trocade 100 mg
Study: 11371662
Drug: Trocade 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trocade 150 mg
Study: 3297678
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg kg‐1 captopril pre‐treated patients
Study: 29804892
Drug: Horticultural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horticultural therapy (HT), 60-minute sessions for 8 weeks
Study: 27155586
Drug: Rivaroxaban mono-therapy
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban mono-therapy
Study: 27155586
Drug: Standard-therapy with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-therapy with enoxaparin followed by vitamin K antagonist (VKA)
Study: 25530057
Drug: Injection at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at a seeking current of 0.8 mA